Akèy › Kansè tete negatif triple › North Carolina › Durham
Etid klinik pou Kansè tete negatif triple nan Durham, NC
12 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Ap rekriteFaz 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Ap rekriteFaz 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Ap rekriteFaz 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Ap rekriteFaz 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Durham
- Kansè nan tete64 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Leksemi mieloïd egi33 etid
- Kansè Metastatik33 etid
- Kansè pwostat32 etid
- Kansè poumon32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Lukemi lenfositè kwonik27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.